AMAG Pharmaceuticals, Inc. (AMAG) Posts Narrower than Expected Q3 Loss; CEO Pereira Resigns

November 4, 2011 7:31 AM EDT
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported Q3 EPS of ($0.78), $0.22 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $16.22 million.

AMAG announced today that Dr. Pereira has resigned from his position as president, CEO and a director of the company, effective immediately. Dr. Pereira will remain a key strategic advisor to the company on certain matters, including the ongoing development and regulatory work related to its broad phase III program for patients with iron deficiency anemia (IDA). AMAG also announced the departure of Gary Zieziula, the company’s chief commercial officer, effective immediately.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Management Changes